Illumina, Inc. (0J8Z.L)
| Previous close | 126.09 |
| Open | 127.51 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 126.33 - 129.58 |
| 52-week range | 89.21 - 232.20 |
| Volume | |
| Avg. volume | 8,482 |
| Market cap | 19.261B |
| Beta (5Y monthly) | 1.15 |
| PE ratio (TTM) | 0.28 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- PR Newswire
European Court of Justice rules in favor of Illumina in jurisdictional appeal
Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, welcomes the European Court of Justice's (ECJ's) judgment today ruling that the European Commission did not have jurisdiction over Illumina's acquisition of GRAIL.
- PR Newswire
Results of GRAIL's Galleri® Multi-Cancer Early Detection Blood Test in Prostate Cancer Published in JCO Precision Oncology
GRAIL, Inc. (Nasdaq: GRAL) a healthcare company whose mission is to detect cancer early when it can be cured, today announced that detailed findings of the performance of its Galleri® multi-cancer early detection (MCED) test in prostate cancer were published in JCO Precision Oncology. The data support the clinical performance of the Galleri test to preferentially screen for aggressive, clinically significant prostate cancer as compared to slow-growing (indolent) cases in the Circulating Cell-fre
- PR Newswire
FDA approves Illumina cancer biomarker test with two companion diagnostics to rapidly match patients to targeted therapies
Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced Food and Drug Administration (FDA) approval of its in vitro diagnostic (IVD) TruSight™ Oncology (TSO) Comprehensive test and its first two companion diagnostic (CDx) indications. This single test interrogates over 500 genes to profile a patient's solid tumor, helping to increase the likelihood of identifying an immuno-oncology biomarker or clinically actionable biomarkers that enable ta
